PSA vaccine for prostate cancer

被引：0
|
作者：
Burton, A
机构：
来源：
LANCET ONCOLOGY | 2002年 / 3卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(02)00767-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：329 / 329
页数：1
相关论文
共 50 条
  • [11] Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.
    Madan, Ravi Amrit
    Tsang, Kwong Yok
    Jochems, Caroline
    Marte, Jennifer L.
    Tucker, Jo A.
    Hodge, James W.
    Singh, Harpreet
    Surolia, Ira
    Coyne, Geraldine Helen O'Sullivan
    Liewehr, David J.
    Steinberg, Seth M.
    Heery, Christopher Ryan
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [12] Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
    Madan, Ravi A.
    Arlen, Philip M.
    Mohebtash, Mahsa
    Hodge, James W.
    Gulley, James L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) : 1001 - 1011
  • [13] Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
    Gulley, James L.
    Madan, Ravi A.
    Tsang, Kwong Y.
    Jochems, Caroline
    Marte, Jennifer L.
    Farsaci, Benedetto
    Tucker, Jo A.
    Hodge, James W.
    Liewehr, David J.
    Steinberg, Seth M.
    Heery, Christopher R.
    Schlom, Jeffrey
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) : 133 - 141
  • [14] Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
    Meidenbauer, N
    Harris, DT
    Spitler, LE
    Whiteside, TL
    PROSTATE, 2000, 43 (02): : 88 - 100
  • [15] PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer
    Ayyildiz, Sema Nur
    Ayyildiz, Ali
    TURKISH JOURNAL OF UROLOGY, 2014, 40 (02): : 82 - 88
  • [16] Complexed PSA and Total PSA in patients with Benign Prostate Hyperplasia and Prostate Cancer
    Tamimi, W.
    Dafterdar, R.
    Mansi, M.
    Alsaad, K.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A111 - A111
  • [17] Phase I clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients
    Head, Jonathan F.
    Daniels, Gregory A.
    McKinney, Michelle
    Ongkeko, Weg
    Sakamoto, Kyoko
    Wang-Rodriguez, Jessica
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [18] Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer.
    Heery, C. R.
    Pinto, P. A.
    Schlom, J.
    Tsang, K. Y.
    Madan, R. A.
    Poole, D.
    Vergati, M.
    Rodriguez, B. Walter
    Merino, M.
    Gulley, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [19] Morphologic changes in prostate cancer samples following intraprostatic PSA-Based vaccine administration
    Val, D.
    Gulley, J. L.
    Pinto, P.
    Schlom, J.
    Linehan, W. M.
    Merino, M. J.
    MODERN PATHOLOGY, 2007, 20 : 181A - 181A
  • [20] Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer
    Shore, N. D.
    Heath, E.
    Nordquist, L.
    Cheng, H.
    Bhatt, K.
    Morrow, M.
    McMullan, T.
    Kraynyak, K.
    Lee, J.
    Sacchetta, B.
    Liu, L.
    Rosencranz, S.
    Tagawa, S. T.
    Parikh, R. A.
    Tutrone, R.
    Garcia, J.
    Whang, Y.
    Kelly, W.
    Csiki, I.
    Bagarazzi, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345